Zai Lab Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZLAB research report →
About the company
Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmune conditions, infectious diseases, and neurological disorders. Currently available products in their portfolio include Zejula, a once-daily small-molecule PARP 1/2 inhibitor; Optune, a medical device leveraging tumor treating fields; NUZYRA, an antimicrobial agent for specific acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors.
- CEO
- Ying Du
- IPO
- 2017
- Employees
- 1,869
- HQ
- Shanghai, CN
Price Chart
- Market Cap
- $2.16B
- P/E
- -11.87
- P/S
- 4.76
- P/B
- 3.19
- EV/EBITDA
- -8.44
- Div Yield
- 0.00%
- Gross Margin
- 57.91%
- Op Margin
- -53.49%
- Net Margin
- -39.29%
- ROE
- -24.29%
- ROIC
- -26.03%
- Revenue
- $460.16M · 15.33%
- Net Income
- $-175,537,000 · 31.73%
- EPS
- $-1.60 · 38.46%
- Op Income
- $-223,572,000
- FCF YoY
- 42.51%
- 52W High
- $41.20
- 52W Low
- $15.96
- 50D MA
- $19.08
- 200D MA
- $21.25
- Beta
- 0.78
- Avg Volume
- 885.26K
Get TickerSpark's AI analysis on ZLAB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 29, 26 | Du Ying | other | 17,970 |
| Jun 30, 26 | Du Ying | sell | 7,026 |
| Jun 29, 26 | Du Ying | other | 17,970 |
| Jun 25, 26 | Edmondson Frazor Titus III | other | 14,600 |
| Jun 26, 26 | Edmondson Frazor Titus III | sell | 4,103 |
| Jun 25, 26 | Edmondson Frazor Titus III | other | 14,600 |
| Jun 25, 26 | Du Ying | other | 58,800 |
| Jun 26, 26 | Du Ying | sell | 24,543 |
| Jun 25, 26 | Du Ying | other | 58,800 |
| Jun 25, 26 | Chen Yajing | other | 6,250 |
Our ZLAB coverage
Recent articles, reports, and earnings notes.
No research on ZLAB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ZLAB report →Similar companies
Peers in the same neighborhood.